Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00653341 | Effect of Insulin Glargine in Insulin Naïve Subjects With Type 2 Diabetes on Oral Hypoglycemic Agent(s) | PHASE3 | COMPLETED | 764 | — | — | Jan 1, 2000 | Oct 1, 2001 | Apr 20, 2009 | 2 | United States, Canada |
| Name | Type | Description |
|---|---|---|
| insulin glargine | DRUG | - |
| NPH human insulin | DRUG | - |
Inclusion Criteria: * Insulin naïve subjects with type 2 diabetes treated with oral hypoglycemic agents * Body mass index between 26 and 40 kg/m2 * HbA1c between 7.5% and 10.0% * Fasting plasma glucose \>7.8 mmol/L and fasting C-peptide \> or =0.25 nmol/L